🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

KIT is a cell surface receptor that acts as the functional regulator of mast cells. Dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders. By inhibiting KIT, our goal is to inactivate and deplete mast cells.

Recently at the THRD All Company meeting we talked about our journey, the importance of where we’ve come from, how we became THRD, and what it will take to succeed in the future. We also made time for a fun scavenger hunt through Cambridge. #OurFutureisBright

Introducing our next next-generation oral KIT inhibitor product candidate, THB335, for the treatment of mast cell-mediated diseases. We plan to file an IND during the first half of 2024.

When old dogs realize they need new tricks…Read how our CEO Natalie Holles is stretching the limits of who she is as a leader after an intense 12 months at Third Harmonic Bio, now appearing in the From the Trenches feature on Bruce Booth website. lifescivc.com/2023/08/growth…

$THRD to participate in the upcoming Morgan Stanley Healthcare Conference on Tuesday, September 12, 2023, from 7:30-7:55 a.m. ET. Join us! ir.thirdharmonicbio.com/news-releases/…

Our team recently had the chance to visit #fenwaypark and #oraclepark to watch America’s favorite pastime. The evenings were a home run and spent enjoying each other’s company and celebrating THRD’s collective achievements. #GoTHRD!

Mast cells act as a primary effector cell of certain inflammatory diseases, such as #urticaria. Targeting mast cells through selective inhibition of KIT represents a novel therapeutic approach and holds the potential to benefit patients with a range of inflammatory diseases.

To hear other differentiating characteristics of oral KIT inhibition, listen to our CEO Natalie Holles’ fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference ir.thirdharmonicbio.com/events/event-d…

Today we are celebrating #UrticariaDay2023 to raise awareness about chronic urticaria, a skin condition marked by itchy, painful hives. We are committed to advancing the next wave of medicine for inflammatory diseases, such as urticaria. #UDAY2023

$THRD reports 3Q’23 financial results ir.thirdharmonicbio.com/news-releases/…

$THRD appoints Chris Murphy as Chief Financial and Business Officer and provides progress update on lead product candidate for mast-cell mediated diseases ir.thirdharmonicbio.com/news-releases/…

Our team was on the ground at #AAAAI24 this weekend to catch a number of presentations featuring the latest advances in chronic urticaria and mast cell targeting. THRD is on track to bring our new investigational treatment option into the clinic during the first half of this year

Our CEO Natalie Holles of $THRD to participate in a fireside chat at the 44th Annual TDCowen Health Care Conference on Tuesday, March 5, 2024, at 1:30 p.m. ET. Join us! ir.thirdharmonicbio.com/news-releases/…

Hear our CEO Natalie Holles describe how we worked our way back to the clinic with our new program to treat mast cell-mediated inflammatory diseases with Brad Loncar at @BiotechTVHQ. #urticaria

$THRD announces 4Q’YE 23 financial results and that we submitted an IND for our new product candidate to treat mast cell-mediated disorders. ir.thirdharmonicbio.com/news-releases/…

Welcome Geoff McDonough, President and CEO of GenerationBio, to the Third Harmonic Board of Directors.

Today at $THRD, we’re celebrating the clearance of our IND, start of our Phase 1 clinical trial and expansion of our outstanding leadership team as part of our 1Q financial results!

"We are excited to expand the $THRD executive team with the appointments of Chris, Dennis and Jennifer to their respective leadership roles in these critical discovery, research and development functions,” said CEO Natalie Holles.

The unique opportunities and collaborative culture make working at THRD truly extraordinary. Watch to hear more on why we think THRD is a special place to work. We're hiring! #GOTHRD youtube.com/watch?v=DT0c9J…

Our science is what gets us excited. We’re building a world-class immunology company targeting mast cells. Learn more and join us! youtube.com/watch?v=aa4tzx…